Wednesday, February 22, 2006

Inotek Pharmaceuticals enters Phase 1 trials with its second clinical compound

BEVERLY, Mass., February 22, 2006 – Inotek Pharmaceuticals Corporation announced today that it has commenced enrollment in a Phase 1 clinical trial for IMS, a novel therapeutic that interrupts signal transduction for inflammation. IMS represents the second compound to have entered clinical trials for Inotek. This study will evaluate the tolerability, safety, and pharmacokinetics of IMS in normal human volunteers. IMS is in development as an oral compound for the treatment of inflammatory bowel disease with initial efficacy trials planned for the treatment of ulcerative colitis. Phase 2 clinical trials are expected to commence toward the end of 2006.

Please download PDF for full press release

#################################################
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation is a private, high-growth, development-stage pharmaceutical company that has leveraged its small molecule chemistry expertise to discover and develop a deep pipeline of therapeutics targeting cell death, DNA repair and inflammatory pathways. Inotek’s lead program is focused on blocking the nuclear DNA repair enzyme poly (ADP- ribose) polymerase (or PARP) that has broad application in a variety of unmet medical needs.

Inotek has one product in Phase 2a clinical development, one product in Phase 1b clinical development and four other products in various stages of pre-clinical development, targeting oncology, cardiovascular, and inflammatory disease. The Company is pursuing indications in hospital-based critical care markets as well as certain specialty care markets. Inotek currently has approximately 130 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its two operational sites in Israel.

  Download PDF

» Return to InotekCorp.com Press Room